Key terms
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALDX news
Yesterday
7:15am ET
Aldeyra in FDA clinical plan for NDA resubmission of reproxalap for DED
Yesterday
7:12am ET
Aldeyra Therapeutics Unveils Reproxalap Development Update
Mar 13
2:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 10
5:27pm ET
Strong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic Partnerships
Mar 07
4:56pm ET
Aldeyra files $200M mixed securities shelf
Mar 04
10:50am ET
Biotech Alert: Searches spiking for these stocks today
Feb 13
4:13pm ET
Aldeyra CEO Speaks at Oppenheimer Healthcare Conference
Jan 07
5:27am ET
BTIG Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)
Jan 04
7:10am ET
Aldeyra announces advancement of RASP modulator platform
Jan 02
9:09am ET
Aldeyra Therapeutics (ALDX) Gets a Buy from BTIG
Dec 31
5:07am ET
BTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
No recent news articles are available for ALDX
ALDX Financials
Key terms
Ad Feedback
ALDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range